Overview
Are You Seeing the Whole Picture? Test Your Skills for Intensifying Therapy in Patients with Type 2 Diabetes
Clinical case review
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
The management of type 2 diabetes (T2D) has evolved rapidly with new agents and changing recommendations. Do you see the whole picture when selecting and intensifying therapy for your patients? Engage in this clinical case review to see whether your treatment selection aligns with guideline recommendations and accounts for cardiovascular disease risks, patient-centric factors, and weight management.
This program is intended for primary care providers in community settings who treat diverse patients with T2D.
The management of T2D has evolved rapidly and several new classes of antidiabetic medications have been introduced over the past decade. For many providers, the rapid expansion of choices and new clinical trial data for the treatment of diabetes have been overwhelming.
Glycemic control targeted at the levels recommended by consensus statements cannot generally be achieved or maintained with oral monotherapy and, for many patients, combination therapy with two oral agents will also be insufficient. Despite the approval of over 40 new treatment options over the last 15 years, evidence indicates, and expert opinion leaders agree, that diabetes therapy intensification continues to be delayed and underutilized, leaving a large proportion of patients with T2D with unacceptable microvascular and macrovascular residual risk.
Considering the epidemic proportions of T2D, it is impossible for all patients to be seen by diabetologists or endocrinologists; therefore, the vast majority of diabetes care in the U.S. is provided in primary care settings. However, in the management of chronic diseases, including diabetes, therapeutic intransigence is well documented and includes both physician and patient barriers.
Detailed knowledge of the various treatment options is necessary for appropriate therapeutic intensification and clinical scenarios must be taken into consideration to avoid side effects and to maximize clinical outcomes.
Upon completion of this activity, learners will be able to:
- Formulate individualized management strategies to reduce long-term complications in patients with T2D
- Describe the benefits of earlier treatment intensification and weight loss in achieving established goals for glycemic control
- Summarize the latest research on the role of incretin-based therapies in patients with T2D, obesity, and obesity-related comorbidities
- Optimize strategies to achieve sustained weight loss in T2D patients based on varied patient characteristics and targets
Provided by the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Lilly.
Jennifer B. Green, MD
Professor of Medicine
Duke University Medical Center
Division of Endocrinology, Metabolism and Nutrition
Durham, NC
Professor of Medicine
Duke University Medical Center
Division of Endocrinology, Metabolism and Nutrition
Durham, NC
Tina K. Thethi, MD, MPH
Associate Investigator
AdventHealth Translational Research Institute and Endocrinologist
AdventHealth Diabetes Institute
Orlando, FL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Jennifer B. Green, MD
Sources of Funding for Research: Boehringer Ingelheim/Lilly, Merck, Roche
Consulting Agreements: Anji, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Merck, NovoNordisk, Pfizer, Sanofi, Valo, Vertex
Tina K. Thethi, MD, MPH
Advisor: Lilly
Sources of Funding for Research: Bayer, Novo Nordisk
Consulting Agreements: Novo Nordisk
Speakers Bureau: Bayer, Lilly
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to engage with the online curriculum and complete the post-activity evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
